Department of Clinical Hematology, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820945815. doi: 10.1177/1533033820945815.
Our study aimed to investigate the correlation of long noncoding RNA maternally expressed gene 3 expression with clinical features, treatment response, and survival profiles in patients with acute myeloid leukemia.
Bone marrow samples of 122 patients with acute myeloid leukemia (prior to treatment) and 30 healthy donors (after enrollment) were collected, and long noncoding RNA maternally expressed gene 3 expression was detected by reverse transcription quantitative polymerase chain reaction. According to median value of long noncoding RNA maternally expressed gene 3 expression in patients with acute myeloid leukemia, they were divided into long noncoding RNA maternally expressed gene 3 high expression and low expression patients (which were further categorized as low---, low--, and low- expression patients).
Long noncoding RNA maternally expressed gene 3 expression was decreased in patients with acute myeloid leukemia compared to healthy donors. Besides, receiver operating characteristic curve displayed that long noncoding RNA maternally expressed gene 3 distinguished patients with acute myeloid leukemia from healthy donors. In patients with acute myeloid leukemia, long noncoding RNA maternally expressed gene 3 low expression was associated with poor-risk stratification but was not correlated with age, gender, French-American-Britain classification, or white blood cell level. For prognosis, complete remission rate was lowest in long noncoding RNA maternally expressed gene 3 low--- expression patients, followed by long noncoding RNA maternally expressed gene 3 low-- expression patients, long noncoding RNA maternally expressed gene 3 low- expression patients, and was highest in long noncoding RNA maternally expressed gene 3 high expression patients; Kaplan-Meier curves displayed that lower long noncoding RNA maternally expressed gene 3 expression was associated with reduced event-free survival and overall survival; Cox regression analysis showed that lower long noncoding RNA maternally expressed gene 3 expression independently predicted decreased event-free survival and worse overall survival in patients with acute myeloid leukemia.
Long noncoding RNA maternally expressed gene 3 may function as a novel marker for effective surveillance and management of acute myeloid leukemia.
本研究旨在探讨长链非编码 RNA 母源表达基因 3 的表达与急性髓系白血病患者的临床特征、治疗反应和生存状况的相关性。
收集 122 例急性髓系白血病患者（治疗前）和 30 例健康供者（入组后）的骨髓样本，采用逆转录定量聚合酶链反应检测长链非编码 RNA 母源表达基因 3 的表达。根据急性髓系白血病患者长链非编码 RNA 母源表达基因 3 表达的中位数，将其分为长链非编码 RNA 母源表达基因 3 高表达和低表达患者（进一步分为低---、低--和低-表达患者）。
与健康供者相比，急性髓系白血病患者长链非编码 RNA 母源表达基因 3 的表达降低。此外，受试者工作特征曲线显示，长链非编码 RNA 母源表达基因 3 可区分急性髓系白血病患者和健康供者。在急性髓系白血病患者中，长链非编码 RNA 母源表达基因 3 低表达与不良风险分层相关，但与年龄、性别、法国-美国-英国分类或白细胞计数无关。在预后方面，长链非编码 RNA 母源表达基因 3 低---表达患者的完全缓解率最低，其次是长链非编码 RNA 母源表达基因 3 低--表达患者、长链非编码 RNA 母源表达基因 3 低-表达患者，长链非编码 RNA 母源表达基因 3 高表达患者的完全缓解率最高；Kaplan-Meier 曲线显示，长链非编码 RNA 母源表达基因 3 表达越低，无事件生存和总生存时间越短；Cox 回归分析显示，长链非编码 RNA 母源表达基因 3 表达越低，独立预测急性髓系白血病患者无事件生存时间缩短和总生存时间恶化。
长链非编码 RNA 母源表达基因 3 可能作为急性髓系白血病有效监测和管理的新标志物。
